CoChat

Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome

Open access
Arrell, D. Kent, Rosenow, Christian S., Yamada, Satsuki, Behfar, Atta, Terzic, Andre · 2020 · npj Regenerative Medicine

The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.

Abstract

Cardiopoietic stem cells have reached advanced clinical testing for ischemic heart failure. To profile their molecular influence on recipient hearts, systems proteomics was here applied in a chronic model of infarction randomized with and without human cardiopoietic stem cell treatment. Multidimensional label-free tandem mass spectrometry resolved and quantified 3987 proteins constituting the cardiac proteome. Infarction altered 450 proteins, reduced to 283 by stem cell treatment. Notably, cell therapy non-stochastically reversed a majority of infarction-provoked changes, remediating 85% of disease-affected protein clusters. Pathway and network analysis decoded functional reorganization, distinguished by prioritization of vasculogenesis, cardiac development, organ regeneration, and differentiation. Subproteome restoration nullified adverse ischemic effects, validated by echo-/electro-cardiographic documentation of improved cardiac chamber size, reduced QT prolongation and augmented ejection fraction post-cell therapy. Collectively, cardiopoietic stem cell intervention transitioned infarcted hearts from a cardiomyopathic trajectory towards pre-disease. Systems proteomics thus offers utility to delineate and interpret complex molecular regenerative outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41536-020-0091-6

Cites

69 of 69 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Cardiopoietic cell therapy reduces infarction altered cardiac proteome. a Of the 3987 identified ventricular proteins, 450 (11.3%) differed significantly between Ctrl and MI (two-fold change, p < 0.01), with z-score transformed agglomerative heatmap showing 243 downregulated (blue) and 207 upregulated (red) proteins in infarcted hearts. b CP cell treatment reduced infarction-induced change to 283 differences from Ctrl (7.1% of total), with heatmap detailing 130 down (blue) and 153 up (red). Ctrl control, MI myocardial infarction, MI + CP MI plus cardiopoietic cell therapy.
Fig. 1 Cardiopoietic cell therapy reduces infarction altered cardiac proteome. a Of the 3987 identified ventricular proteins, 450 (11.3%) differed significantly between Ctrl and MI (two-fold change, p < 0.01), with z-score transformed agglomerative heatmap showing 243 downregulated (blue) and 207 upregulated (red) proteins in infarcted hearts. b CP cell treatment reduced infarction-induced change to 283 differences from Ctrl (7.1% of total), with heatmap detailing 130 down (blue) and 153 up (red). Ctrl control, MI myocardial infarction, MI + CP MI plus cardiopoietic cell therapy.CC BY · PubMed Central
Fig. 2 Reversal of infarcted proteome and predicted upstream regulators. a A majority of proteins altered by MI responded to cardiopoietic (CP) cell therapy (n = 292, 64.9%), either by full (n = 64, 14.2%, blue) or partial (n = 228, 50.7%, red) reversal, whereas 158 proteins (35.1%, green) did not. A larger proportion of downregulated (70%) than upregulated (59%) proteins were responsive to therapy. b Full reversal, following cell treatment, occurred for 32 proteins upregulated and 32 downregulated by infarction. Proteins altered in MI vs. Ctrl (gray bars) were considered fully reversed when altered in the opposite direction in MI + CP vs. MI (red bars) such that MI + CP did not differ from Ctrl. c Partial reversal occurred for 91 proteins upregulated and 137 downregulated by infarction. Proteins considered partially reversed were altered in the opposite direction in MI + CP (versus MI), and either without reaching significance versus MI and not differing from Ctrl; or significantly differing from both Ctrl and MI. d Reversed subproteome (n = 292 proteins) interpretation by pathway analysis identified 78 upstream regulators possessing z-scores for both infarction-induced (MI versus Ctrl) and reversed (MI + CP versus MI) proteome changes, with large z-scores predictive of activation (positive z-score) or inhibition (negative z-score). z-score inverse correlation suggested upstream regulators activated by MI were inhibited by cell therapy, and vice versa. Several cardiac and stem cell transcription factors localize to the upper left quadrant, indicating predicted inhibition in MI, with re-activation upon CP cell therapy. Ctrl control, MI myocardial infarction, MI + CP MI plus cardiopoietic cell therapy.
Fig. 2 Reversal of infarcted proteome and predicted upstream regulators. a A majority of proteins altered by MI responded to cardiopoietic (CP) cell therapy (n = 292, 64.9%), either by full (n = 64, 14.2%, blue) or partial (n = 228, 50.7%, red) reversal, whereas 158 proteins (35.1%, green) did not. A larger proportion of downregulated (70%) than upregulated (59%) proteins were responsive to therapy. b Full reversal, following cell treatment, occurred for 32 proteins upregulated and 32 downregulated by infarction. Proteins altered in MI vs. Ctrl (gray bars) were considered fully reversed when altered in the opposite direction in MI + CP vs. MI (red bars) such that MI + CP did not differ from Ctrl. c Partial reversal occurred for 91 proteins upregulated and 137 downregulated by infarction. Proteins considered partially reversed were altered in the opposite direction in MI + CP (versus MI), and either without reaching significance versus MI and not differing from Ctrl; or significantly differing from both Ctrl and MI. d Reversed subproteome (n = 292 proteins) interpretation by pathway analysis identified 78 upstream regulators possessing z-scores for both infarction-induced (MI versus Ctrl) and reversed (MI + CP versus MI) proteome changes, with large z-scores predictive of activation (positive z-score) or inhibition (negative z-score). z-score inverse correlation suggested upstream regulators activated by MI were inhibited by cell therapy, and vice versa. Several cardiac and stem cell transcription factors localize to the upper left quadrant, indicating predicted inhibition in MI, with re-activation upon CP cell therapy. Ctrl control, MI myocardial infarction, MI + CP MI plus cardiopoietic cell therapy.CC BY · PubMed Central
Fig. 3 Infarction susceptible protein classes respond to cell therapy. Categorical impact was assessed for 33 functional classes into which proteins were allocated, with radial graphs plotting changes induced by myocardial infarction without (MI vs. Ctrl; upregulated in a, downregulated in b) or with cardiopoietic cell therapy (MI + CP vs. Ctrl; upregulated in c, downregulated in d). Radial displacement (red projection) indicates intra-class percentage differing from controls (Categorical Δ, %). Blue circles represent total proteome change (Total Δ, %). Proteins upregulated by infarction were reduced for most categories (26% overall) by cell therapy (a versus c), and likewise for categories downregulated by infarction (b versus d), which reduced 46.5% overall. For each graph a–d, n indicates number of proteins changed (>2-fold, p < 0.01). Functional categories are arrayed alphabetically, with identities and number of proteins listed.
Fig. 3 Infarction susceptible protein classes respond to cell therapy. Categorical impact was assessed for 33 functional classes into which proteins were allocated, with radial graphs plotting changes induced by myocardial infarction without (MI vs. Ctrl; upregulated in a, downregulated in b) or with cardiopoietic cell therapy (MI + CP vs. Ctrl; upregulated in c, downregulated in d). Radial displacement (red projection) indicates intra-class percentage differing from controls (Categorical Δ, %). Blue circles represent total proteome change (Total Δ, %). Proteins upregulated by infarction were reduced for most categories (26% overall) by cell therapy (a versus c), and likewise for categories downregulated by infarction (b versus d), which reduced 46.5% overall. For each graph a–d, n indicates number of proteins changed (>2-fold, p < 0.01). Functional categories are arrayed alphabetically, with identities and number of proteins listed.CC BY · PubMed Central
Fig. 4 Functional enrichment at proteome and network levels indicative of cell therapy impact. a Screening of proteins differentially expressed by myocardial infarction (–CP) for Ingenuity Pathway Analysis (IPA) enrichment (p < 0.001) of cardiovascular system development and physiological functions revealed prioritization of cardiovascular disease and abnormal morphology. b IPA screening of the cell therapy differential proteome (+CP) indicated a transition from infarction, with numerous enriched functions prioritizing vasculogenesis and associated vascular properties. Asterisks indicate annotations common to a and b, shown in blue or orange if reduced or increased in significance, respectively, following cell therapy (+CP versus –CP). c Venn diagram indicates enriched (Benjamini–Hochberg corrected p < 0.001) Gene Ontology (GO) Biological Processes shared between or unique to the –CP and +CP networks from Supplementary Data Fig. 2. Bubble plots indicate processes unique to each network, with circle diameter proportional to intra-cluster number of annotations, and −log(p-value) for each circle representing the mean of all annotations represented within the cluster. Clusters present in both networks are noted between the –CP and +CP bubble plots, with matching categories shown in identical colors.
Fig. 4 Functional enrichment at proteome and network levels indicative of cell therapy impact. a Screening of proteins differentially expressed by myocardial infarction (–CP) for Ingenuity Pathway Analysis (IPA) enrichment (p < 0.001) of cardiovascular system development and physiological functions revealed prioritization of cardiovascular disease and abnormal morphology. b IPA screening of the cell therapy differential proteome (+CP) indicated a transition from infarction, with numerous enriched functions prioritizing vasculogenesis and associated vascular properties. Asterisks indicate annotations common to a and b, shown in blue or orange if reduced or increased in significance, respectively, following cell therapy (+CP versus –CP). c Venn diagram indicates enriched (Benjamini–Hochberg corrected p < 0.001) Gene Ontology (GO) Biological Processes shared between or unique to the –CP and +CP networks from Supplementary Data Fig. 2. Bubble plots indicate processes unique to each network, with circle diameter proportional to intra-cluster number of annotations, and −log(p-value) for each circle representing the mean of all annotations represented within the cluster. Clusters present in both networks are noted between the –CP and +CP bubble plots, with matching categories shown in identical colors.CC BY · PubMed Central
Fig. 5 Cell therapy-reduced disease associations and -nullified adverse effects validated in vivo. a Ingenuity Pathway Analysis (IPA) interrogation of the infarction altered proteome for cardiovascular disease annotations revealed enriched functions (57 gray bars, p < 0.001), of which only 15 remained in the cell therapy altered proteome (red asterisks). b In IPA Tox Function analysis, hypergeometric overrepresentation predicted 24 cardiac adverse effects associated with the infarcted proteome (gray), 20 of which were significant (p < 0.05). Following interpretation of the reversed subproteome, nearly all adverse effects were predicted to be nullified by cell therapy (red). c–e Infarcted animals were randomized to those without (MI) versus those receiving cardiopoietic (CP) cell therapy (MI + CP), and assessed by echocardiography and electrocardiography for cardiac structure c, electrophysiology d and contractility e. Ischemic cardiomyopathy (MI, n = 8) was characterized by left ventricular dilation and pump failure, quantified by increased end-systolic volume c and decreased ejection fraction e, respectively, 4 weeks post- relative to pre-randomization. In contrast, CP cell therapy (MI + CP, n = 16) reversed infarction induced cardiac enlargement c and improved performance e. QT prolongation, a parameter of ventricular repolarization associated with tachyarrhythmia, observed in MI (n = 8) was blunted in MI + CP (n = 8; d). Bars in c–e indicate standard error of the mean.
Fig. 5 Cell therapy-reduced disease associations and -nullified adverse effects validated in vivo. a Ingenuity Pathway Analysis (IPA) interrogation of the infarction altered proteome for cardiovascular disease annotations revealed enriched functions (57 gray bars, p < 0.001), of which only 15 remained in the cell therapy altered proteome (red asterisks). b In IPA Tox Function analysis, hypergeometric overrepresentation predicted 24 cardiac adverse effects associated with the infarcted proteome (gray), 20 of which were significant (p < 0.05). Following interpretation of the reversed subproteome, nearly all adverse effects were predicted to be nullified by cell therapy (red). c–e Infarcted animals were randomized to those without (MI) versus those receiving cardiopoietic (CP) cell therapy (MI + CP), and assessed by echocardiography and electrocardiography for cardiac structure c, electrophysiology d and contractility e. Ischemic cardiomyopathy (MI, n = 8) was characterized by left ventricular dilation and pump failure, quantified by increased end-systolic volume c and decreased ejection fraction e, respectively, 4 weeks post- relative to pre-randomization. In contrast, CP cell therapy (MI + CP, n = 16) reversed infarction induced cardiac enlargement c and improved performance e. QT prolongation, a parameter of ventricular repolarization associated with tachyarrhythmia, observed in MI (n = 8) was blunted in MI + CP (n = 8; d). Bars in c–e indicate standard error of the mean.CC BY · PubMed Central
Fig. 6 Cardiopoietic cell therapy redirects infarction modified proteome toward pre-disease state. a Principal component (PC) analysis of differential protein expression segregated myocardial infarction hearts (MI, blue) away from pre-disease controls (Ctrl, red), with cardiopoietic cell therapy (MI + CP, green) counterparts positioned in-between. PC1 represents 25%, PC2 13%, and PC3 11% of total data. b Euclidean squared distance between cohorts was maximal for MI versus Ctrl (2.28 × 105) representing the full extent of disease induced transition, i.e., 100% displacement. Distance between cardiopoietic cell therapy cohort and control (MI + CP versus Ctrl) was substantially lower (1.18 × 105), i.e., 52% of disease-induced displacement. Moreover, the MI + CP versus MI distance was 1.59 × 105, estimating that treatment outcome (MI + CP) response displacement returned ≈57% of the way [1.18 × 105/(1.18 × 105 + 1.59 × 105)] toward pre-disease.
Fig. 6 Cardiopoietic cell therapy redirects infarction modified proteome toward pre-disease state. a Principal component (PC) analysis of differential protein expression segregated myocardial infarction hearts (MI, blue) away from pre-disease controls (Ctrl, red), with cardiopoietic cell therapy (MI + CP, green) counterparts positioned in-between. PC1 represents 25%, PC2 13%, and PC3 11% of total data. b Euclidean squared distance between cohorts was maximal for MI versus Ctrl (2.28 × 105) representing the full extent of disease induced transition, i.e., 100% displacement. Distance between cardiopoietic cell therapy cohort and control (MI + CP versus Ctrl) was substantially lower (1.18 × 105), i.e., 52% of disease-induced displacement. Moreover, the MI + CP versus MI distance was 1.59 × 105, estimating that treatment outcome (MI + CP) response displacement returned ≈57% of the way [1.18 × 105/(1.18 × 105 + 1.59 × 105)] toward pre-disease.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 69 references

Cited by

See all 30

Metadata

Authors
Arrell, D. K., Rosenow, C. S., Yamada, S., Behfar, A., & Terzic, A.
Affiliations
Mayo Clinic (US)
Venue
npj Regenerative Medicine
Published
2020-03-12
Volume
5
Issue
1
Pages
5-5
ISSN
2057-3995 (ISSN-L)
OpenAlex
W3012451848
Cited by
30
References
69
Citations by year
2026: 3 · 2025: 3 · 2024: 4 · 2023: 4 · 2022: 5 · 2021: 7 · 2020: 4
FWCI
2.59
Type
journal article
Language
en
Open access
Licence
Locations
  • npj Regenerative Medicine (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Regenerative Medicine Minnesota (021218BT001)
  • National Institutes of Health (HL-07111)
  • National Heart, Lung, and Blood Institute (R01HL134664, T32HL007111)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Congenital heart defects research
  • Health Sciences › Medicine › Surgery › Tissue Engineering and Regenerative Medicine
Keywords
stem cell therapy, myocardial infarction, cardiac proteome, ischemic heart failure, vasculogenesis, cardiac regeneration, heart development, ejection fraction, QT prolongation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome. https://app.cochat.ai/papers/10.1038/s41536-020-0091-6
The paper
Arrell, D. K., Rosenow, C. S., Yamada, S., Behfar, A., & Terzic, A. (2020). Cardiopoietic stem cell therapy restores infarction-altered cardiac proteome. npj Regenerative Medicine. https://doi.org/10.1038/s41536-020-0091-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.